RecensMedical, Inc.: debt-to-equity, ROE and more
KOSDAQ, Legal name RecensMedical, Inc.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 72.1%
- Equity ratio
- 58.1%
- ROE
- -274.0%
- Op. margin
- -120.5%
- Rev. growth
- 41.0%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | n/a | -624.0% | n/a | -11,484.7% | n/a |
| FY2022 separate | n/a | -326.1% | n/a | -3,359.3% | 591.1% |
| FY2023 consolidated | n/a | -551.5% | n/a | -218.1% | 1,987.5% |
| FY2024 consolidated | n/a | -450.6% | n/a | -226.2% | 8.5% |
| FY2025 consolidated | 72.1% | 58.1% | -274.0% | -120.5% | 41.0% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩40.0M | ₩276.4M | ₩5.8B | ₩6.3B | ₩8.8B |
| Operating profit | -₩4.6B | -₩9.3B | -₩12.6B | -₩14.2B | -₩10.6B |
| Pre-tax income | -₩22.8B | -₩41.5B | -₩7.6B | -₩7.8B | -₩19.1B |
| Net income | -₩22.8B | -₩41.5B | -₩7.6B | -₩7.8B | -₩19.1B |
| Total assets | ₩6.3B | ₩24.3B | ₩15.2B | ₩20.1B | ₩12.0B |
| Total liabilities | ₩45.5B | ₩103.5B | ₩99.2B | ₩110.7B | ₩5.0B |
| Total equity | -₩39.2B | -₩79.2B | -₩84.0B | -₩90.6B | ₩7.0B |
| Paid-in capital | ₩183.2M | ₩1.7B | ₩1.7B | ₩1.7B | ₩4.7B |
| Debt/equity (source value) | 0.0% | 0.0% | 0.0% | 0.0% | 72.1% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2016-10-18
- Listed
- 26/03/31
- Employees
- 55
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 2301110265867
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 리센스메디컬Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.